Sofosbuvir and simeprevir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation

International Journal of Organ Transplantation Medicine

Volumn 7, Issue 1, 2016, Pages 38-45

  Issa, D ^a   Eghtesad, B ^a   Zein, N N ^a   Yerian, L ^a   Cruise, M ^a   Alkhouri, N ^a   Adams, R ^a   Hanouneh, I A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Fibrosis; Hepacivirus; Jaundice; Liver cirrhosis; Liver transplantation; Obstructive; Pancreatitis; Pruritus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETRAVIRINE; GAMMA GLUTAMYLTRANSFERASE; MYCOPHENOLATE MOFETIL; PEGINTERFERON; PREDNISONE; RALTEGRAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TENOFOVIR; VIRUS RNA;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUTE PANCREATITIS; ADULT; AGED; ALPHA ANTITRYPSIN DEFICIENCY; ARTICLE; ASCITES; BLOOD TRANSFUSION; CAUSE OF DEATH; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; ECHOGRAPHY; END STAGE LIVER DISEASE; ENDOTRACHEAL INTUBATION; ESCHERICHIA COLI INFECTION; ESOPHAGUS VARICES; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERTENSION; JAUNDICE; LEUKOCYTOSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MIXED INFECTION; MULTIPLE ORGAN FAILURE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; RESPIRATORY FAILURE; SEPSIS; STEATOSIS; VIRUS LOAD;

EID: 84957704575     PISSN: 20086482     EISSN: 20086490     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Verna EC, Brown RS, Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006;10:919-40.
2. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96.
3. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78.
4. Cimsit B, Assis D, Caldwell C, et al. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc 2011;43:905-8.
5. Satapathy SK, Sclair S, Fiel MI, et al. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res 2011;41:328-39.
6. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010;16:1228-35.
7. Al Nahdi N, Ford JA, Greanya ED, et al. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol 2013;12:156-60.
8. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013;13:1601-5.
9. Fontana RJ, Hughes EA, Appelman H, et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012;18:1053-9.
10. Kim B, Trivedi A, Thung SN, Grewal P. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis 2014;34:108-12.
11. Guillouche P, Feray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011;33:163-74.
12. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012;142:1132-9 e1131.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
14. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
15. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
16. Liu J, Du J, Wang P, et al. A 2'-deoxy-2'-fluoro-2'-C-methyl uridine cyclopentyl carbocyclic analog and its phosphoramidate prodrug as inhibitors of HCV NS5B polymerase. Nucleosides Nucleotides Nucleic Acids 2012;31:277-85.
17. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
18. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146:430-41 e436.
19. Murakami K, Kawagishi N, Ishida K, et al. Fibrosing cholestatic hepatitis developing within one month after living donor liver transplantation for chronic hepatitis C-related cirrhosis: a case report. Transplant Proc 2014;46:995-8.
20. Duarte-Rojo A, Budhraja V, Veldt BJ, et al. Interleukin-28B and fibrosing cholestatic hepatitis in post-transplant hepatitis C: a case-control study and literature review. Liver Transpl 2013;19:1311-17.
21. Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012;18:1464-70.
22. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65.